| Document |
Document Title |
|
WO/2024/102063A1 |
The invention pertains to a method for profiling a cancer tumour, wherein the method comprises the steps of; in a tissue sample from a cancer tumour, Preparing at least one tumour slide from histological preparations; Acquiring a image o...
|
|
WO/2024/102226A1 |
Provided herein are methods and compositions related to assaying (for example, for potency) bacterial drug substances and/or drug products comprising bacteria and/or microbial extracellular vesicles (mEVs).
|
|
WO/2024/101305A1 |
A culture vessel (10) comprises a container body (11) that has an opening (11a) that opens in a slit shape, and that vertically accommodates a sheet-like object (membrane filter (100)) through the opening (11a).
|
|
WO/2024/102199A1 |
Methods for classifying a lupus disease state of a patient is provided. The method can include analyzing a data set comprising or derived from gene expression measurements of at least 2 genes selected from genes listed in Table 3, and Ta...
|
|
WO/2024/064728A3 |
Provided herein are biopanning methods for identifying peptides that bind to one or more glial cell subtypes, and peptides identified using the methods described herein. In some embodiments, provided herein are biopanning methods for ide...
|
|
WO/2024/099346A1 |
The present invention provides use of a compound as represented by formula I or a pharmaceutically acceptable salt or ester thereof in the preparation of a drug for treating ASC-caspase-1 pathway-based inflammasome activation-mediated di...
|
|
WO/2024/101945A1 |
The present invention relates to a nanoparticle, a nanoparticle complex comprising anti-5'-tRH-GlyGCC bound thereto, and a pharmaceutical composition for preventing or treating cancer comprising same. The present invention may provide an...
|
|
WO/2024/100556A1 |
Biomarkers that can be used for the detection or diagnosis of disease states, preferably cancer (e.g., triple negative breast cancer (TNBC)) disease states, to the prediction of disease prognosis and/or a treatment outcome, to the identi...
|
|
WO/2024/100377A1 |
Disclosed herein is a method for a diagnostic tool to calculate a renal allograft recipient's risk for acute rejection.
|
|
WO/2024/099079A1 |
Disclosed herein are an amplification structure, a rapid nucleic acid detection chip comprising the amplification structure, a device comprising the rapid nucleic acid detection chip, a corresponding amplification method, a rapid nucleic...
|
|
WO/2024/102722A1 |
The present disclosure relates to methods of treating a tumor (or cancer) with an unmethylated MGMT promoter in a subject in need thereof. In some aspects, the method comprises administering to the subject an anti-cancer treatment, compr...
|
|
WO/2024/099959A1 |
The present disclosure relates to supports comprising an optically transparent substrate and at least one sample spot on the surface of the support, devices for determining a single molecule event comprising said supports and methods for...
|
|
WO/2024/059153A3 |
The current disclosure provides an improved sensitivity assay for detecting and quantifying nucleic acids in a sample. The assay utilizes target recycling amplification process (TRAP) for the digital detection of nucleic acids in tandem ...
|
|
WO/2024/102081A1 |
The present disclosure seeks to improve some aspects of the currently existing protein detection and immunodiagnostic methods such as sensitivity, detection limit and testing time. To this end, the present disclosure relates to a nanopor...
|
|
WO/2024/101905A1 |
The present invention relates to an SNP marker for determining the place of origin of Scapharca subcrenata and a use thereof. The SNP marker for determining the place of origin of Scapharca subcrenata developed as the present invention c...
|
|
WO/2023/212744A3 |
Provided herein are methods for diagnosing ALS, or determining risk of developing ALS. The methods include detection of a fusion as described herein. The methods can include detecting genomic fusions, fused transcripts, or fusion protein...
|
|
WO/2024/098152A1 |
This disclosure relates to catalytic nucleic acids, catalytic nucleic acid probes, biosensors, lateral flow devices, and kits for detecting the presence or absence of eosinophil peroxidase. Also provided are methods for detecting the pre...
|
|
WO/2024/103018A2 |
The present disclosure relates generally to methods for accurately predicting the risk of cancer-associated venous thromboembolism (CAT) and/or preventing CAT in cancer patients using ctDNA as a biomarker.
|
|
WO/2024/102736A1 |
The present disclosure relates in some aspects to methods and compositions for immobilization of nucleic acids for in situ detection in a biological sample or a matrix embedding the biological sample.
|
|
WO/2024/101303A1 |
An evaluation method of an anticancer agent that includes the following steps in this order: a step of culturing a cell structure containing stromal cells, in which a gene encoding a viable cell marker protein has been knocked out, and c...
|
|
WO/2024/100545A1 |
The present invention proposes novel derivatives of phthalazinium dicyanomethanides (I), a process for manufacturing same, and the use thereof in the functionalization of peptides and proteins, in the attachment of biological polymers to...
|
|
WO/2024/102996A1 |
Systems, methods, and compositions can be used to generate a therapeutic cell. The system can be an fully closed, automated system. The system, methods and compositions can intake cells of a subject and modify the cells to generate thera...
|
|
WO/2024/103044A1 |
Compositions and methods involving Bacteroides ovatus are provided herein in certain aspects to reduced GVHD, including GVHD associated with Bacteroides thetaiotaomicron. This includes therapeutic compositions comprising the bacteria Bac...
|
|
WO/2024/098185A1 |
Methods and kits for sequencing a nucleic acid molecule are provided, which include utilizing four different compounds that are respectively derivatives of nucleotides A, (T/U), C and G, wherein the hydroxyl at the 3'-position of sugar o...
|
|
WO/2024/098116A1 |
The present invention relates to CRISPR/Cas-based biosensing materials, assays and methods. In particular, the technology relates to ultrasensitive CRISPR/Cas-based detection methods for nucleic acid assays using special molecular constr...
|
|
WO/2024/098146A1 |
Provided herein are an a2-3 disialylated PSA protein standard and an a2-6 disialylated PSA protein standard, as well as various methods for measuring the relative (fractional) amount of the total N-acetylneuraminic acid (Neu5Ac) that is ...
|
|
WO/2024/100258A1 |
The present invention relates to a library comprising a plurality of detection probes suitable for detection of a set of analytes of interest, each detection probe comprising an analyte-specific binding domain and a nucleic acid moiety, ...
|
|
WO/2024/098295A1 |
The present invention provides a digital PCR method for an integrated micro-droplet chip, which belongs to the technical field of digital PCR analyzers. The method comprises: controlling a sample adding cavity and a gas-liquid interface ...
|
|
WO/2024/064766A3 |
As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial usin...
|
|
WO/2024/101294A1 |
[Problem] To provide a method for obtaining a sequence for a nucleic acid including an artificial nucleic acid, more specifically a method for amplifying a sequence for a nucleic acid including a non-cyclic artificial nucleic acid to amp...
|
|
WO/2024/102761A1 |
Provided herein are methods of detecting tumor nucleic acids in a biological sample of a subject.
|
|
WO/2024/100070A1 |
The invention relates to the field of molecular biology and more particularly that of clinical and industrial microbiology. More specifically, the present invention relates to a culture medium for detecting microorganisms, comprising, as...
|
|
WO/2024/101758A1 |
The present invention relates to a novel nucleic acid isothermal amplification method using extension-mediated self-folding. Specifically, the present invention relates to a primer set for extension-mediated self-folding isothermal ampli...
|
|
WO/2024/098369A1 |
Disclosed herein are an isolated microRNA molecule, a Parkinson's disease in-vitro diagnostic kit based on a DNA hexahedron, and use thereof. The microRNA molecule miR26690 provided by the present application is highly expressed in an ex...
|
|
WO/2024/076981A3 |
Methods of amplifying libraries after introduction of dihydrouracil (DHU) residues by methods such as TET-assisted Pyridine Borane Sequencing (TAPS), and variants of TAPS including TAPS with blocking by β-glucosylation (TAPSβ) and Chem...
|
|
WO/2024/102484A1 |
The disclosed technology relates to methods for improved risk stratification of Acute Myeloid Leukemia (AML.) patients, and more particularly, for improved risk stratification of adult and pediatric AML patients using inflammation gene s...
|
|
WO/2024/101323A1 |
The present disclosure pertains to a method for producing a cell population, the method comprising: a step for separating cells from a three-dimensional tissue body formed in vitro and containing the cells and an extracellular matrix com...
|
|
WO/2024/102839A1 |
Compositions, assays, methods, diagnostic methods, kits, and diagnostic kits are disclosed for the specific and differential detection of SARS-CoV-2, Flu A, Flu B, RSV A, and RSV B from samples, including veterinary samples, clinical sam...
|
|
WO/2024/101823A1 |
The present invention relates to a biomarker for predicting immunotherapeutic responsiveness based on spatial transcriptome analysis and uses thereof and, in particular, to: a marker composition for predicting the responsiveness of cance...
|
|
WO/2024/099592A1 |
The present invention relates to a spinach plant that is resistant to downy mildew caused by Peronospora farinosa. The present invention further relates to a resistance gene that confers resistance to downy mildew in spinach plants and m...
|
|
WO/2024/099816A1 |
The present invention relates to a method of determining complement activity, wherein said method comprises determining classical complement pathway activity, determining alternative complement pathway activity, and/or determining lectin...
|
|
WO/2024/102913A1 |
The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing a kidney disease by administering an Angiopoietin Like 3 (ANGPTL3) inhibitor and a Solute Carrier Family 5 Memb...
|
|
WO/2024/102360A1 |
Devices for isolating, collecting and/or transferring target molecules to an assay area, comprising an enclosure having a top section adapted to receive a sample, a central hollow body section or other area or cavity suitable for receivi...
|
|
WO/2024/097970A1 |
Methods and materials for improving outcomes for ex vivo perfused organs are provided herein. For example, this document provides methods and materials that can be used to assess and treat lungs during ex vivo perfusion prior to transpla...
|
|
WO/2024/093522A1 |
The present disclosure relates to methods, compositions, and kits for concentrating and purifying one or more target analyte (s) from a bulk fluid sample. In some embodiments, the methods involve at least two first aqueous two-phase syst...
|
|
WO/2024/095238A1 |
Provided is a magnetosome comprising a doped mineral. Further provided is method for large-scale production of magnetosomes comprising a doped mineral, the method comprising maintaining in a fermentation vessel under continuous fermentat...
|
|
WO/2024/097899A1 |
Polynucleotides, expression constructs, compositions, kits and method relating to genetic disorders are disclosed. Some embodiments provided herein encompass variants of a protein that relate to a genetic disorder. Also contemplated are ...
|
|
WO/2024/092740A1 |
Provided is a method for detecting intercellular interaction. The method comprises: (1) preparing a first cell expressing a TCR activation response element and a reporter molecule, the first cell expressing a TCR; (2) co-incubating an an...
|
|
WO/2024/093523A1 |
The present disclosure relates to methods, compositions, and kits for isolating target nucleic acids below a target size from a sample comprising nucleic acid components. In some embodiments, the methods involve one or more aqueous two-p...
|
|
WO/2024/096125A1 |
The present disclosure provides a technique for efficiently designing or producing a bacterial preparation utilizing a bacterium capable of exhibiting a desired trait or a desired efficacy. More specifically, the present disclosure provi...
|
